Aura Biosciences Stock Performance
| AURA Stock | USD 8.96 0.08 0.90% |
On a scale of 0 to 100, Aura Biosciences holds a performance score of 5. The firm shows a Beta (market volatility) of 2.01, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Aura Biosciences will likely underperform. Please check Aura Biosciences' semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to make a quick decision on whether Aura Biosciences' price patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Aura Biosciences are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Aura Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.35 | Five Day Return 2.62 | Year To Date Return (0.33) | Ten Year Return (39.19) | All Time Return (39.19) |
1 | Aura Biosciences Touts Promising Data From Eye Cancer Candidate | 09/12/2024 |
2 | Aura Announces Q3 2024 Production Results, the Fifth Consecutive LTM Production Increase and on Track to Meet the Companys 2024 Guidance | 10/10/2024 |
3 | Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer in Ong... | 10/17/2024 |
4 | Mark Plavsic Sells 7,383 Shares of Aura Biosciences, Inc. Stock | 10/18/2024 |
5 | Aura Biosciences CFO Julie Feder sells shares worth 302,361 | 10/21/2024 |
6 | Insider Trading | 10/25/2024 |
7 | Aura Minerals to Acquire Bluestone Resources | 10/28/2024 |
8 | Disposition of 553 shares by Amy Elazzouzi of Aura Biosciences at 10.7385 subject to Rule 16b-3 | 10/29/2024 |
9 | Aura Biosciences CEO Elisabet de los Pinos sells 98,787 in stock | 10/30/2024 |
10 | Youll Have To Win A Japanese Lottery If You Want A Midnight Purple Nissan Z | 11/08/2024 |
11 | Aura Biosciences Posts Earnings Results, Beats Expectations By 0.02 EPS | 11/15/2024 |
12 | Disposition of 11822 shares by Hopkins Janet Jill of Aura Biosciences at 9.3608 subject to Rule 16b-3 | 11/18/2024 |
13 | Aura Biosciences chief medical officer sells 110,663 in stock | 11/19/2024 |
14 | Acquisition by Srivastava Sapna of 16000 shares of Aura Biosciences at 12.83 subject to Rule 16b-3 | 11/22/2024 |
| Begin Period Cash Flow | 122.4 M |
Aura |
Aura Biosciences Relative Risk vs. Return Landscape
If you would invest 773.00 in Aura Biosciences on August 28, 2024 and sell it today you would earn a total of 115.00 from holding Aura Biosciences or generate 14.88% return on investment over 90 days. Aura Biosciences is currently generating 0.2874% in daily expected returns and assumes 3.8425% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Aura, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aura Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aura Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aura Biosciences, and traders can use it to determine the average amount a Aura Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0748
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AURA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.84 actual daily | 34 66% of assets are more volatile |
Expected Return
| 0.29 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Aura Biosciences is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aura Biosciences by adding it to a well-diversified portfolio.
Aura Biosciences Fundamentals Growth
Aura Stock prices reflect investors' perceptions of the future prospects and financial health of Aura Biosciences, and Aura Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aura Stock performance.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 288.28 M | ||||
| Shares Outstanding | 49.95 M | ||||
| Price To Book | 2.54 X | ||||
| EBITDA | (83.7 M) | ||||
| Net Income | (76.41 M) | ||||
| Cash And Equivalents | 122.13 M | ||||
| Cash Per Share | 4.17 X | ||||
| Total Debt | 19.56 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.97 X | ||||
| Book Value Per Share | 3.51 X | ||||
| Cash Flow From Operations | (63.85 M) | ||||
| Earnings Per Share | (1.73) X | ||||
| Market Capitalization | 443.57 M | ||||
| Total Asset | 255.07 M | ||||
| Retained Earnings | (287.31 M) | ||||
| Working Capital | 219.44 M | ||||
About Aura Biosciences Performance
By analyzing Aura Biosciences' fundamental ratios, stakeholders can gain valuable insights into Aura Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Aura Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aura Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.31) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.34) | (0.32) |
Things to note about Aura Biosciences performance evaluation
Checking the ongoing alerts about Aura Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aura Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aura Biosciences had very high historical volatility over the last 90 days | |
| Net Loss for the year was (76.41 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Aura Biosciences currently holds about 122.13 M in cash with (63.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.17. | |
| Aura Biosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Aura Biosciences chief medical officer sells 110,663 in stock |
- Analyzing Aura Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aura Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Aura Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aura Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aura Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aura Biosciences' stock. These opinions can provide insight into Aura Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Aura Stock analysis
When running Aura Biosciences' price analysis, check to measure Aura Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aura Biosciences is operating at the current time. Most of Aura Biosciences' value examination focuses on studying past and present price action to predict the probability of Aura Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aura Biosciences' price. Additionally, you may evaluate how the addition of Aura Biosciences to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |